LadRx News

LadRx | 10-Q: Quarterly report

SEC announcementMay 15 18:40 · Announcements

Xoma to Pay $1M to LadRx as Rare Disease Therapy Undergoes FDA Review

Seeking AlphaJan 12 20:44

Xoma To Make $1 Mln Milestone Payment To LadRx After FDA Accepts Zevra's NDA For Arimoclomol

RTTNewsJan 12 05:37

LadRx Issues 2024 Update to Shareholders

FDA Acceptance of Arimoclomol Triggers $1 Million Payment LadRx Corporation (OTCQB:LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer

BusinesswireJan 9 21:00

XOMA Acquires Drug Rights From LadRx for $5M

Seeking AlphaJun 23, 2023 00:23

XOMA Acquires Royalty, Milestone Rights for Two Assets From LadRx

XOMA (XOMA) said Thursday it has acquired the royalty and milestone rights for two assets from LadRx for $5 million. The assets are arimoclomol, an investigational treatment for neurogenerative disord

MT NewswiresJun 22, 2023 22:03

Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively

Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 O

BenzingaJun 22, 2023 19:39

LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million With XOMA Corporation

XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assetsLOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB:

BusinesswireJun 22, 2023 19:30

LadRx Announces Reverse Stock Split Effective As Of May 17, 2023 >LADX

LadRx Announces Reverse Stock Split Effective As Of May 17, 2023 >LADX

Dow JonesMay 18, 2023 20:00

LadRx To Carry Out 1-for-100 Reverse Stock Split On May 18th, 2023

May 11th - $LadRx(LADX.US)$ is about to implement a 1-for-100 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from May 18th, 2023.$LadRx(LADX.US)$ slipped 5.74%

Futu NewsMay 11, 2023 07:35

LadRx Announces Reverse Stock Split >LADX

LadRx Announces Reverse Stock Split >LADX

Dow JonesMay 10, 2023 20:00

LadRx, Oncology Drug Developer, Files for Nasdaq Uplisting, Public Offering

Seeking AlphaApr 15, 2023 05:50

LadRx (NASDAQ:CYTR) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Wednesday. The firm set a "hold" rating on the stock.LadRx Stock PerformanceLadRx

Defense WorldMar 29, 2023 13:34

LadRx Highlights Patent Issued for Its LADR Technology

LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today hi

BusinesswireMar 27, 2023 21:05

Comparing LadRx (OTCMKTS:CYTR) & Inhibrx (NASDAQ:INBX)

LadRx (OTCMKTS:CYTR – Get Rating) and Inhibrx (NASDAQ:INBX – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the streng

Financial News LiveMar 21, 2023 16:36

LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates

LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announce

BusinesswireMar 15, 2023 21:04

Comparing LadRx (OTCMKTS:CYTR) and Inhibrx (NASDAQ:INBX)

LadRx (OTCMKTS:CYTR – Get Rating) and Inhibrx (NASDAQ:INBX – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength o

Defense WorldMar 14, 2023 17:21

LadRx (NASDAQ:CYTR) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research note issued on Sunday. The firm set a "hold" rating on the stock.LadRx Price PerformanceLad

Defense WorldMar 5, 2023 16:33

LadRx (OTCMKTS:CYTR) & MiNK Therapeutics (NASDAQ:INKT) Critical Contrast

LadRx (OTCMKTS:CYTR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on

Defense WorldFeb 26, 2023 14:33

StockNews.com Begins Coverage on LadRx (NASDAQ:CYTR)

StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Thursday. The brokerage issued a hold rating on the stock. LadRx Stock Performance LadRx has a 52-

kopsourceFeb 12, 2023 18:01